4SC-205 is under clinical development by 4SC and currently in Phase I for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase I drugs for Castration-Resistant Prostate Cancer (CRPC) have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how 4SC-205’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
4SC-205 is under development for the treatment of solid tumors including hormone refractory prostate cancer, breast cancer refractory to hormone treatment, ovarian cancer, malignant melanoma, head and neck cancer, non-small cell lung cancer, bladder cancer, colorectal cancer, kidney cancer, relapsed and refractory multiple myeloma and malignant lymphomas. It is administered orally. The drug candidate is a small molecule inhibitor of the human kinesin spindle protein Eg5 which is of crucial importance for proper cell division (mitosis) by mediating chromosome separation to the daughter cells. The drug candidate is developed based on Virtual High Throughput Screening (vHTS) platform, 4SCan. It was under development for liver cancer and lung cancer.
It was under development for the treatment of liver and lung cancer in china and for liver cancer in United States.
4SC is a biopharmaceutical company that develops small molecule drugs for the treatment of cancer. The company’s product portfolio focuses on epigenetics, cancer stem cells and cancer immunotherapy. Its small molecule product pipeline comprises of Resminostat and Domatinostat (4SC-202), both are histone deacetylase (HDAC) inhibitor. 4SC’s research programs are related to cancer stem cells, ion channel blockers and cytokine modulation. The company develops and commercializes its products through partnerships and collaborations with pharmaceutical and biotech companies mainly in the European and Asian markets. 4SC is headquartered in Planegg-Martinsried, Germany.